1H-1,2,4-Triazole-5-carboxamide, 3-(phenylmethyl)-N-[(3S)-2,3,4,5-tetrahydro-5-methyl-4-oxopyrido[3,2-b][1,4]oxazepin-3-yl]- manufacturers
- Eclitasertib
-
- $108.00
-
2026-07-27
- CAS:2125450-76-0
- Purity: 99.85%
- Supply Ability: 10g
|
| | 1H-1,2,4-Triazole-5-carboxamide, 3-(phenylmethyl)-N-[(3S)-2,3,4,5-tetrahydro-5-methyl-4-oxopyrido[3,2-b][1,4]oxazepin-3-yl]- Basic information |
| Product Name: | 1H-1,2,4-Triazole-5-carboxamide, 3-(phenylmethyl)-N-[(3S)-2,3,4,5-tetrahydro-5-methyl-4-oxopyrido[3,2-b][1,4]oxazepin-3-yl]- | | Synonyms: | 1H-1,2,4-Triazole-5-carboxamide, 3-(phenylmethyl)-N-[(3S)-2,3,4,5-tetrahydro-5-methyl-4-oxopyrido[3,2-b][1,4]oxazepin-3-yl]-;SAR-443122;SAR-443122,RIPK,Receptor-interacting protein kinases,SAR443122,DNL 758,DNL758,Eclitasertib,Inhibitor,DNL-758,inhibit,RIP kinase,SAR 443122;(S)-5-Benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide;Eclitasertib, 10 mM in DMSO;DNL-758;Eclitasertib,5-benzyl-N-[(3S)-5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][1,4]oxazepin-3-yl]-2H-1,2,4-triazole-3-carboxamide;Eclitasertib | | CAS: | 2125450-76-0 | | MF: | C19H18N6O3 | | MW: | 378.38 | | EINECS: | | | Product Categories: | | | Mol File: | 2125450-76-0.mol | ![1H-1,2,4-Triazole-5-carboxamide, 3-(phenylmethyl)-N-[(3S)-2,3,4,5-tetrahydro-5-methyl-4-oxopyrido[3,2-b][1,4]oxazepin-3-yl]- Structure](CAS/20210111/GIF/2125450-76-0.gif) |
| | 1H-1,2,4-Triazole-5-carboxamide, 3-(phenylmethyl)-N-[(3S)-2,3,4,5-tetrahydro-5-methyl-4-oxopyrido[3,2-b][1,4]oxazepin-3-yl]- Chemical Properties |
| density | 1.44±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 125 mg/mL (330.36 mM; Need ultrasonic) | | form | Solid | | pka | 8.74±0.40(Predicted) | | color | White to light yellow |
| | 1H-1,2,4-Triazole-5-carboxamide, 3-(phenylmethyl)-N-[(3S)-2,3,4,5-tetrahydro-5-methyl-4-oxopyrido[3,2-b][1,4]oxazepin-3-yl]- Usage And Synthesis |
| Uses | Eclitasertib (DNL-758) is a potent receptor-interacting protein kinase 1 (RIPK1) inhibitor with an IC50 of 0.0375 μΜ[1]. | | in vivo | Eclitasertib (po, single dose) inhibits TNF-alpha induced hypothermia in mouse models[2]. | Animal Model: | mouse TNF-alpha induced hypothermia models[2] | | Dosage: | | | Administration: | po, single dose | | Result: | Ameliorated TNF-alpha induced hypothermia. |
| | IC 50 | RIPK1 | | References | [1] Anthony A. ESTRADA, et al. Compounds, compositions and methods. WO2017136727A2. [2] Darwish I, et al., Rip1k inhibitors. WO2021203011 |
| | 1H-1,2,4-Triazole-5-carboxamide, 3-(phenylmethyl)-N-[(3S)-2,3,4,5-tetrahydro-5-methyl-4-oxopyrido[3,2-b][1,4]oxazepin-3-yl]- Preparation Products And Raw materials |
|